Enhancement of subunit vaccine delivery with zinc-carnosine coordination polymer through the addition of mannan

[Display omitted] Vaccines represent a pivotal health advancement for preventing infection. However, because carrier systems with repeated administration can invoke carrier-targeted immune responses that diminish subsequent immune responses (e.g., PEG antibodies), there is a continual need to develo...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 656; p. 124076
Main Authors Roque, John A., Lukesh, Nicole Rose, Hendy, Dylan A., Dixon, Timothy A., Islam, Md Jahirul, Ontiveros-Padilla, Luis, Pena, Erik S., Lifshits, Liubov M., Simpson, Sean R., Batty, Cole J., Bachelder, Eric M., Ainslie, Kristy M.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 10.05.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] Vaccines represent a pivotal health advancement for preventing infection. However, because carrier systems with repeated administration can invoke carrier-targeted immune responses that diminish subsequent immune responses (e.g., PEG antibodies), there is a continual need to develop novel vaccine platforms. Zinc carnosine microparticles (ZnCar MPs), which are composed of a one-dimensional coordination polymer formed between carnosine and the metal ion zinc, have exhibited efficacy in inducing an immune response against influenza. However, ZnCar MPs’ limited suspendability hinders clinical application. In this study, we address this issue by mixing mannan, a polysaccharide derived from yeast, with ZnCar MPs. We show that the addition of mannan increases the suspendability of this promising vaccine formulation. Additionally, since mannan is an adjuvant, we illustrate that the addition of mannan increases the antibody response and T cell response when mixed with ZnCar MPs. Mice vaccinated with mannan + OVA/ZnCar MPs had elevated serum IgG and IgG1 levels in comparison to vaccination without mannan. Moreover, in the mannan + OVA/ZnCar MPs vaccinated group, mucosal washes demonstrated increased IgG, IgG1, and IgG2c titers, and antigen recall assays showed enhanced IFN-γ production in response to MHC-I and MHC-II immunodominant peptide restimulation, compared to the vaccination without mannan. These findings suggest that the use of mannan mixed with ZnCar MPs holds potential for subunit vaccination and its improved suspendability further promotes clinical translation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2024.124076